Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer

CONCLUSION: Among patients who responded to rucaparib, a substantial proportion achieved responses lasting ≥1 year. These analyses demonstrate the relationship between DOR to PARP inhibitor treatment and molecular characteristics in HGOC, such as presence of reversion-resistant BRCA structural variants.PMID:34602290 | DOI:10.1016/j.ygyno.2021.08.030

Source: Gynecologic Oncology - October 4, 2021 Category: Cancer & Oncology Authors: Elizabeth M Swisher Rebecca S Kristeleit Amit M Oza Anna V Tinker Isabelle Ray-Coquard Ana Oaknin Robert L Coleman Howard A Burris Carol Aghajanian David M O'Malley Alexandra Leary Stephen Welch Diane Provencher Geoffrey I Shapiro Lee-May Chen Ronnie Shap Source Type: research